This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sodha, N. Articles by Garrett, M. D. Search for Related Content PubMed PubMed Citation Articles by Sodha, N. Articles by Garrett, M. D.

Rare Germ Line CHEK2 Variants Identified in Breast Cancer Families Encode Proteins That Show Impaired Activation

¹ Royal Marsden NHS Foundation Trust; ² Cancer Research UK Centre for Cancer Therapeutics; and ³ International Agency of Research on Cancer, Lyon, France, and ⁴ Section of Cancer Genetics, The Institute of Cancer Research, Sutton, United Kingdom

Requests for reprints: Nayanta Sodha, Cancer Genetics Unit, Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom. Phone: 44-208-722-4238; Fax: 44-208-722-4225; E-mail: Nayanta.Sodha{at}icr.ac.uk.

Germ line mutations in CHEK2, the gene that encodes the Chk2 serine/threonine kinase activated in response to DNA damage, have been found to confer an increased risk of some cancers. We have previously reported the presence of the common deleterious 1100delC and four rare CHEK2 mutations in inherited breast cancer. Here, we report that predictions made by bioinformatic analysis on the rare mutations indicate that two of these, delE161 (483-485delAGA) and R117G, are likely to be deleterious. We show that the proteins encoded by 1100delC and delE161 are both unstable and inefficiently phosphorylated at Thr⁶⁸ in response to DNA damage, a step necessary for the oligomerization of Chk2. Oligomerization is in turn necessary for additional phosphorylation and full activation of the protein. A second rare mutation, R117G, is phosphorylated at Thr⁶⁸ but fails to show a mobility shift on DNA damage, suggesting that it fails to become further phosphorylated and hence fully activated. Our results indicate that delE161 and R117G encode nonfunctional proteins and are therefore likely to be pathogenic. The findings from the biochemical analysis correlate well with predictions made by bioinformatics analysis. In addition, the results imply that these mutations, as well as 1100delC, cannot act in a dominant-negative manner to cause cancer, and tumorigenesis in association with these mutations may be due to haploinsufficiency. (Cancer Res 2006; 66(18): 8966-70)

This article has been cited by other articles:

				A. Mahajan, C. Yuan, H. Lee, E. S.-W. Chen, P.-Y. Wu, and M.-D. Tsai Structure and Function of the Phosphothreonine-Specific FHA Domain Sci. Signal., December 23, 2008; 1(51): re12 - re12. [Abstract] [Full Text] [PDF]